Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors

Baylor College of Medicine, Houston, Texas 77030, USA.

OBJECTIVES. This study sought to describe in detail the pharmacokinetics and pharmacodynamics of chimeric monoclonal 7E3 Fab (c7E3 Fab) and to compare platelet responses to adenosine diphosphate (ADP) and the 11-amino acid thrombin receptor-activating peptide (TRAP [SFLLRNPNDKY-NH2]) in patients undergoing elective coronary angioplasty. BACKGROUND. Inhibition of platelet aggregation with monoclonal antibody c7E3 Fab directed against glycoprotein (GP) IIb/IIIa has been shown to reduce ischemic complications after angioplasty and is being considered for treatment of other acute ischemic syndromes. METHODS. Patients undergoing elective coronary angioplasty received aspirin (325 mg orally), heparin (12,000 U intravenously) and a bolus of c7E3 Fab (0.25 mg/kg body weight). Surface GPIIb/IIIa receptor blockade and aggregation in response to 20 mumol/liter ADP, 5 micrograms/ml collagen and 7.5 and 15 mumol/liter TRAP were assessed. RESULTS. Surface GPIIb/IIIa receptor blockade by c7E3 Fab was 80% 2 h after injection and decreased to 50% at 24 h. Platelet aggregation in response to 20 mumol/liter ADP was inhibited by 73% at 2 h, and this inhibition decreased to 27% at 24 h. Platelet aggregation in response to 7.5 mumol/liter TRAP was inhibited by 53% at 2 h and 30% at 24 h. In contrast, aggregation in response to 15 mumol/liter TRAP was inhibited only 37% at 2 h and 10% at 24 h (p < 0.001 and p = 0.006, respectively vs. 20 mumol/liter ADP). Addition of exogenous c7E3 Fab to platelet-rich plasma led to more complete inhibition of 7.5 mumol/liter TRAP-induced aggregation. CONCLUSIONS. After c7E3 Fab treatment, inhibition of platelet aggregation depends on the agonist and can be overcome by increased thrombin activity but is restored if additional c7E3 Fab is added to block additional GPIIb/IIIa receptors. This phenomenon may be related to an internal pool of GPIIb/IIIa receptors joining the surface membrane and has implications concerning the duration of therapy with c7E3 Fab for patients with unstable angina or acute myocardial infarction.

This article has been cited by other articles:

				A. Y. Fung, J. Saw, A. Starovoytov, C. Densem, P. Jokhi, S. J. Walsh, R. S. Fox, K. H. Humphries, E. Aymong, D. R. Ricci, et al. Abbreviated Infusion of Eptifibatide After Successful Coronary Intervention: The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) Randomized Trial J. Am. Coll. Cardiol., March 10, 2009; 53(10): 837 - 845. [Abstract] [Full Text] [PDF]

				S. S. Patel, H. Rana, and D. A. N. Mascarenhas Intracoronary Abciximab Use in Patients Undergoing PCI at a Community Hospital: A Single Operator Experience Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2008; 13(2): 89 - 93. [Abstract] [PDF]

				O. F. Bertrand, R. De Larochelliere, J. Rodes-Cabau, G. Proulx, O. Gleeton, C. Manh Nguyen, J.-P. Dery, G. Barbeau, B. Noel, E. Larose, et al. A Randomized Study Comparing Same-Day Home Discharge and Abciximab Bolus Only to Overnight Hospitalization and Abciximab Bolus and Infusion After Transradial Coronary Stent Implantation Circulation, December 12, 2006; 114(24): 2636 - 2643. [Abstract] [Full Text] [PDF]

				S. Akar, M. A. Ozcan, H. Ates, O. Gurler, I. Alacacioglu, G. H. Ozsan, N. Akkoc, S. Ozkan, F. Demirkan, and F. Onen Circulated Activated Platelets and Increased Platelet Reactivity in Patients With Behcet's Disease Clinical and Applied Thrombosis/Hemostasis, October 1, 2006; 12(4): 451 - 457. [Abstract] [PDF]

				S. Goto, N. Tamura, and H. Ishida Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions J. Am. Coll. Cardiol., July 21, 2004; 44(2): 316 - 323. [Abstract] [Full Text] [PDF]

				D. J. Moliterno and A. W. Chan Glycoprotein IIb/IIIa inhibition in early intent-to-stent treatment of acute coronary syndromes: EPISTENT, ADMIRAL, CADILLAC, and TARGET J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 49S - 54S. [Abstract] [Full Text] [PDF]

				H.-C. Yoon and F. J. Miller Jr. Using a Peptide Inhibitor of the Glycoprotein IIb/IIIa Platelet Receptor: Initial Experience in Patients with Acute Peripheral Arterial Occlusions Am. J. Roentgenol., March 1, 2002; 178(3): 617 - 622. [Abstract] [Full Text] [PDF]

				B. E. Tardiff, L. K. Jennings, R. A. Harrington, D. Gretler, R. F. Potthoff, D. A. Vorchheimer, P. R. Eisenberg, A. M. Lincoff, M. Labinaz, D. M. Joseph, et al. Pharmacodynamics and Pharmacokinetics of Eptifibatide in Patients With Acute Coronary Syndromes: Prospective Analysis From PURSUIT Circulation, July 24, 2001; 104(4): 399 - 405. [Abstract] [Full Text] [PDF]

				S. R. Steinhubl, J. D. Talley, G. A. Braden, J. E. Tcheng, P. J. Casterella, D. J. Moliterno, F. I. Navetta, P. B. Berger, J. J. Popma, G. Dangas, et al. Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention : Results of the GOLD (AU-Assessing Ultegra) Multicenter Study Circulation, May 29, 2001; 103(21): 2572 - 2578. [Abstract] [Full Text] [PDF]

				F.-J. Neumann, W. Hochholzer, G. Pogatsa-Murray, A. Schomig, and M. Gawaz Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1323 - 1328. [Abstract] [Full Text] [PDF]

				E. I. Lev, J. I. Osende, M. F. Richard, J. A. Robbins, J. A. Delfin, O. Rodriguez, S. K. Sharma, T. Jayasundera, J. J. Badimon, and J. D. Marmur Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function J. Am. Coll. Cardiol., March 1, 2001; 37(3): 847 - 855. [Abstract] [Full Text] [PDF]

				A. M. Lincoff, L. A. LeNarz, G. J. Despotis, P. K. Smith, J. E. Booth, R. E. Raymond, S. K. Sapp, C. F. Cabot, J. E. Tcheng, R. M. Califf, et al. Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials Ann. Thorac. Surg., August 1, 2000; 70(2): 516 - 526. [Abstract] [Full Text] [PDF]

				S. A. Coulter, C. P. Cannon, K. A. Ault, E. M. Antman, F. Van de Werf, A. A. J. Adgey, C. M. Gibson, R. P. Giugliano, M. A. Mascelli, J. Scherer, et al. High Levels of Platelet Inhibition With Abciximab Despite Heightened Platelet Activation and Aggregation During Thrombolysis for Acute Myocardial Infarction : Results From TIMI (Thrombolysis In Myocardial Infarction) 14 Circulation, June 13, 2000; 101(23): 2690 - 2695. [Abstract] [Full Text] [PDF]

				A. M. Lincoff, R. M. Califf, and E. J. Topol Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease J. Am. Coll. Cardiol., April 1, 2000; 35(5): 1103 - 1115. [Abstract] [Full Text] [PDF]

				A. T. Nurden, C. Poujol, C. Durrieu-Jais, and P. Nurden Platelet Glycoprotein IIb/IIIa Inhibitors : Basic and Clinical Aspects Arterioscler Thromb Vasc Biol, December 1, 1999; 19(12): 2835 - 2840. [Full Text] [PDF]

				S. R. Steinhubl, K. Kottke-Marchant, D. J. Moliterno, M. L. Rosenthal, N. K. Godfrey, B. S. Coller, E. J. Topol, and A. M. Lincoff Attainment and Maintenance of Platelet Inhibition Through Standard Dosing of Abciximab in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention Circulation, November 9, 1999; 100(19): 1977 - 1982. [Abstract] [Full Text] [PDF]

				S. Harder, C. M. Kirchmaier, H. J. Krzywanek, D. Westrup, J.-W. Bae, and H. K. Breddin Pharmacokinetics and Pharmacodynamic Effects of a New Antibody Glycoprotein IIb/IIIa Inhibitor (YM337) in Healthy Subjects Circulation, September 14, 1999; 100(11): 1175 - 1181. [Abstract] [Full Text] [PDF]

				R. M. Scarborough, N. S. Kleiman, and D. R. Phillips Platelet Glycoprotein IIb/IIIa Antagonists : What Are the Relevant Issues Concerning Their Pharmacology and Clinical Use? Circulation, July 27, 1999; 100(4): 437 - 444. [Abstract] [Full Text] [PDF]

				P. Nurden, C. Poujol, C. Durrieu-Jais, J. Winckler, R. Combrie, L. Macchi, C. Bihour, C. Wagner, R. Jordan, and A. T. Nurden Labeling of the Internal Pool of GP IIb-IIIa in Platelets by c7E3 Fab Fragments (abciximab): Flow and Endocytic Mechanisms Contribute to the Transport Blood, March 1, 1999; 93(5): 1622 - 1633. [Abstract] [Full Text] [PDF]

				C. Bihour, C. Durrieu-Jais, L. Macchi, C. Poujol, P. Coste, P. Besse, P. Nurden, and A. T. Nurden Expression of Markers of Platelet Activation and the Interpatient Variation in Response to Abciximab Arterioscler Thromb Vasc Biol, February 1, 1999; 19(2): 212 - 219. [Abstract] [Full Text] [PDF]

				J. K. Mickelson, M. N. Ali, N. S. Kleiman, N. M. Lakkis, T. W. Chow, B. J. Hughes, and C. W. Smith Chimeric 7e3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty J. Am. Coll. Cardiol., January 1, 1999; 33(1): 97 - 106. [Abstract] [Full Text] [PDF]

				R.F. Storey, R.G. Wilcox, and S. Heptinstall Differential Effects of Glycoprotein IIb/IIIa Antagonists on Platelet Microaggregate and Macroaggregate Formation and Effect of Anticoagulant on Antagonist Potency : Implications for Assay Methodology and Comparison of Different Antagonists Circulation, October 20, 1998; 98(16): 1616 - 1621. [Abstract] [Full Text] [PDF]

				N. S. Kleiman, A. M. Lincoff, D. J. Kereiakes, D. P. Miller, F. V. Aguirre, K. M. Anderson, H. F. Weisman, R. M. Califf, and E. J. Topol Diabetes Mellitus, Glycoprotein IIb/IIIa Blockade, and Heparin : Evidence for a Complex Interaction in a Multicenter Trial Circulation, May 19, 1998; 97(19): 1912 - 1920. [Abstract] [Full Text] [PDF]

				M. A. Mascelli, E. T. Lance, L. Damaraju, C. L. Wagner, H. F. Weisman, and R. E. Jordan Pharmacodynamic Profile of Short-term Abciximab Treatment Demonstrates Prolonged Platelet Inhibition With Gradual Recovery From GP IIb/IIIa Receptor Blockade Circulation, May 5, 1998; 97(17): 1680 - 1688. [Abstract] [Full Text] [PDF]

				S. J. Shattil, H. Kashiwagi, and N. Pampori Integrin Signaling: The Platelet Paradigm Blood, April 15, 1998; 91(8): 2645 - 2657. [Full Text] [PDF]

				M. A. Mascelli, S. Worley, N. J. Veriabo, E. T. Lance, S. Mack, T. Schaible, H. F. Weisman, and R. E. Jordan Rapid Assessment of Platelet Function With a Modified Whole-Blood Aggregometer in Percutaneous Transluminal Coronary Angioplasty Patients Receiving Anti-GP IIb/IIIa Therapy Circulation, December 2, 1997; 96(11): 3860 - 3866. [Abstract] [Full Text]

				D. R. Phillips, W. Teng, A. Arfsten, L. Nannizzi-Alaimo, M. M. White, C. Longhurst, S. J. Shattil, A. Randolph, J. A. Jakubowski, L. K. Jennings, et al. Effect of Ca2+ on GP IIb-IIIa Interactions With Integrilin : Enhanced GP IIb-IIIa Binding and Inhibition of Platelet Aggregation by Reductions in the Concentration of Ionized Calcium in Plasma Anticoagulated With Citrate Circulation, September 2, 1997; 96(5): 1488 - 1494. [Abstract] [Full Text]

				D. J. Kereiakes, N. Kleiman, J. J. Ferguson, J. P. Runyon, T. M. Broderick, N. A. Higby, L. H. Martin, G. Hantsbarger, S. McDonald, and R. J. Anders Sustained Platelet Glycoprotein IIb/IIIa Blockade With Oral Xemilofiban in 170 Patients After Coronary Stent Deployment Circulation, August 19, 1997; 96(4): 1117 - 1121. [Abstract] [Full Text]

				T. H. Muller, H. Weisenberger, R. Brickl, H. Narjes, F. Himmelsbach, and J. Krause Profound and Sustained Inhibition of Platelet Aggregation by Fradafiban, a Nonpeptide Platelet Glycoprotein IIb/IIIa Antagonist, and Its Orally Active Prodrug, Lefradafiban, in Men Circulation, August 19, 1997; 96(4): 1130 - 1138. [Abstract] [Full Text]

				E. M. Ohman, N. S. Kleiman, G. Gacioch, S. J. Worley, F. I. Navetta, J. D. Talley, H. V. Anderson, S. G. Ellis, M. D. Cohen, D. Spriggs, et al. Combined Accelerated Tissue-Plasminogen Activator and Platelet Glycoprotein IIb/IIIa Integrin Receptor Blockade With Integrilin in Acute Myocardial Infarction: Results of a Randomized, Placebo-Controlled, Dose-Ranging Trial Circulation, February 18, 1997; 95(4): 846 - 854. [Abstract] [Full Text]

				R. K. Aggarwal, D. C. Ireland, M. A. Azrin, M. D. Ezekowitz, D. P. de Bono, and A. H. Gershlick Antithrombotic Potential of Polymer-Coated Stents Eluting Platelet Glycoprotein IIb/IIIa Receptor Antibody Circulation, December 15, 1996; 94(12): 3311 - 3317. [Abstract] [Full Text]